Hospira Inc. (HSP): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Hospira ( HSP) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.8%. By the end of trading, Hospira fell $0.39 (-1.1%) to $34.23 on light volume. Throughout the day, 1,169,830 shares of Hospira exchanged hands as compared to its average daily volume of 2,170,300 shares. The stock ranged in price between $34.19-$34.70 after having opened the day at $34.67 as compared to the previous trading day's close of $34.62. Other companies within the Health Care sector that declined today were: Genvec ( GNVC), down 33.6%, Electromed ( ELMD), down 11.1%, Redhill Biopharma ( RDHL), down 7.9% and American Shared Hospital Services ( AMS), down 7.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. Hospira has a market cap of $5.7 billion and is part of the drugs industry. Shares are up 10.6% year to date as of the close of trading on Friday. Currently there are no analysts that rate Hospira a buy, 2 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Hospira as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and weak operating cash flow.

On the positive front, Theragenics Corporation ( TGX), down 36.2%, Alimera ( ALIM), down 27.3%, Opexa Therapeutics ( OPXA), down 26.0% and Unilife Corporation ( UNIS), down 25.3% , were all gainers within the health care sector with Gilead ( GILD) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

New Lifetime High For Hospira (HSP)

Hospira (HSP) Showing Signs Of Being Strong And Under The Radar

Trade-Ideas: Hospira (HSP) Is Today's New Lifetime High Stock

10 Best S&P 500 Health Care Stocks

10 Best S&P 500 Stocks This Year